Showing 371-380 of 21407 results for "".
- Night Owls Are More Likely to Develop Type 2 Diabetes – And It’s Not Just Because of an Unhealthy Lifestyle, Dutch Study Findshttps://reachmd.com/news/night-owls-are-more-likely-to-develop-type-2-diabetes-and-its-not-just-because-of-an-unhealthy-lifestyle-dutch-study-finds/2468140/Night owls have a higher BMI, larger waists, more hidden body fat and are almost 50% more likely to develop type 2 diabetes (T2D) than those who go to bed earlier, new research to be presented at the Annual Meeting of the European Association fo
- Few Patients Can Treat Their Type 2 Diabetes Through Weight Loss Alonehttps://reachmd.com/news/few-patients-can-treat-their-type-2-diabetes-through-weight-loss-alone/2456962/Sign up for a full digest of all the best opinions of the week in our Voices Dispatches emailSign up to our free weekly Voices newsletterVery few patients diagnosed with type 2 diabetes are able to treat their c
- Adenosine Signaling and Metabolic Regulation: Exploring Obesity-Driven Type 2 Diabeteshttps://reachmd.com/news/adenosine-signaling-and-metabolic-regulation-exploring-obesity-driven-type-2-diabetes/2474708/Recent advancements in Diabetes and Endocrinology have illuminated the critical function of adenosine receptor-mediated pathways. Through investigating mechanisms like ATP catabolism and receptor-mediated regulation, researchers have identified interactions between
- Medication Adherence and Glycemic Control in Older Adults with Type 2 Diabeteshttps://reachmd.com/news/medication-adherence-and-glycemic-control-in-older-adults-with-type-2-diabetes/2474295/Research reveals a paradox in diabetes management for older patients. Despite consistently high medication adherence, many elderly individuals do not reach optimal glycemic control. This discrepancy is driven by complex treatment regimens, behavior
- AI-Driven Subclassification of Type 2 Diabetes Utilizing Continuous Glucose Monitoringhttps://reachmd.com/news/ai-driven-subclassification-type-2-diabetes-utilizing-continuous-glucose-monitoring/2470872/What's New A new AI-based tool developed at Stanford Medicine offers a promising method to improve diabetes classification by identifying distinct subtypes using continuous glucose monitors. Significance This advancement can significantly enhance per
- For Type 1 Diabetes Distress, Focus First on Managing Emotionshttps://reachmd.com/news/for-type-1-diabetes-distress-focus-first-on-managing-emotions/2467007/The most effective way to reduce the distress that comes with having diabetes – and improve glucose control – is to focus on managing the emotional strain of living with the condition, a new study of adults that was led by researchers at UC San Francisco has found.</
- FreeDM2 Trial Links Real-Time Cgm To Better HbA1c In Type 2 Diabeteshttps://reachmd.com/news/freedm2-trial-links-real-time-cgm-to-better-hba1c-in-type-2-diabetes/2486833/Key Takeaways Greater HbA1c reduction was reported with real-time CGM than with finger-prick monitoring at 16 and 32 weeks. The randomized comparison included 303 participants with type 2 diabetes treated with basal insulin plus SGLT2 inhibitors, GLP-1
- Revolutionizing Kidney Transplant Outcomes: The Role of Anti-Obesity Drugs in Type 2 Diabetes Patientshttps://reachmd.com/news/revolutionizing-kidney-transplant-outcomes-the-role-of-anti-obesity-drugs-in-type-2-diabetes-patients/2471494/Recent clinical observations indicate that integrating anti-obesity drugs may significantly improve outcomes for kidney transplant recipients with type 2 diabetes by reducing post-surgical complications including organ failure, inflammation, organ rejection, and early death
- GLP-1 Drugs: A Promising Therapeutic Approach for Kidney Transplant Recipients with Type 2 Diabeteshttps://reachmd.com/news/glp-1-drugs-a-promising-therapeutic-approach-for-kidney-transplant-recipients-with-type-2-diabetes/2471590/Recent investigations highlight emerging evidence that GLP-1 drugs, traditionally used for anti‐obesity and metabolic regulation, may also reduce organ failure rates and improve survival in kidney transplant recipients with type 2 diabetes. Expl
- GLP-1 Receptor Agonists: A New Frontier in Managing Cancer Risk for Type 2 Diabeteshttps://reachmd.com/news/glp-1-receptor-agonists-a-new-frontier-in-managing-cancer-risk-for-type-2-diabetes/2471579/A recent study published in JAMA Network Open has revealed that patients with type 2 diabetes treated with GLP-1 receptor agonists may experience a significantly reduced risk of developing hematologic cancers compared to those on traditional therapies such as insulin and me